Related Experiment Video
Updated: Aug 26, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
Top advances in lymphoma for 2021
1Washington University in St Louis School of Medicine, St Louis, MO, USA.
Cancer
|October 6, 2022
Summary
New CAR T-cell therapies and targeted agents are revolutionizing lymphoma treatment. These advancements offer improved outcomes for diffuse large B-cell lymphoma and new options for relapsed, refractory, and indolent lymphomas.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Recent therapeutic advancements have significantly changed lymphoma treatment paradigms.
- Chimeric antigen receptor (CAR) T-cell therapy, antibody-drug conjugates, and bispecific T-cell redirectors are key innovations.
- Targeting tonic B-cell receptor signaling also represents a novel therapeutic strategy.
Purpose of the Study:
- To review the paradigm shifts in lymphoma treatment driven by novel therapeutic agents in 2021.
- To highlight the impact of these therapies on diffuse large B-cell lymphoma (DLBCL), indolent lymphomas, and marginal zone lymphoma.
- To discuss the evolving role of CAR T-cell therapy and other targeted agents in various lymphoma settings.
Main Methods:
- Review of recent clinical studies and therapeutic approvals in lymphoma treatment.
- Analysis of data from pivotal trials such as the POLARIX study for DLBCL.
- Evaluation of the efficacy and safety of novel agents including CAR T-cells, bispecific antibodies, and targeted small molecules.
Main Results:
- The POLARIX study demonstrated improved outcomes for frontline DLBCL treatment with a standard backbone plus rituximab.
- CAR T-cell therapies have become a preferred option over autologous transplantation for relapsed/refractory lymphomas, enabling earlier treatment.
- CAR T-cell therapies show promising activity in indolent lymphomas, and agents like mosunetuzumab offer new hope for heavily pretreated patients.
- Zanubrutinib approval provides a crucial later-line therapy option for marginal zone lymphoma, particularly for elderly or less fit patients.
Conclusions:
- Novel immunotherapies and targeted agents have substantially improved lymphoma treatment efficacy and patient outcomes.
- CAR T-cell therapy is expanding its role from aggressive to indolent lymphomas, offering durable responses.
- The therapeutic landscape continues to evolve, with a shift towards safer and more durable treatment constructs, displacing older agents like PI3K inhibitors.
Related Concept Videos
01:16Primary Lymphoid Organs
4.3K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
4.3K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
642
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
642
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:18Lymphoid Cells and Tissues
1.4K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.4K
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K